Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren't Buying It
THE SO WHAT
The gap between AI drug-discovery promises and pharma CEO skepticism is a reminder that validation, regulation, and commercial risk—not model accuracy—govern adoption in this sector. If you’re selling AI into biopharma, anchor on trial design, failure rates, and regulatory evidence packages, not just faster target discovery.
READ THE SOURCE
MORE FROM THE WIRE
Applied AIPartnering with Edelbyte: Data Infrastructure That Keeps Up With AI's Curiosity
If agents are going to hammer your internal systems with orders of magnitude more queries than humans ever did, the real constraint becomes data infra cost and latency, not model quality. Teams building agents should be budgeting for a new class of OLAP-style infra like Edelbyte’s, not assuming the existing warehouse can take the load.
Applied AIApple is racing to make Siri more agentic
Apple is treating agentic Siri as a must-close gap with OpenAI and Meta, not a nice-to-have—pressure from John Ternus on Craig Federighi means the iOS system UX is about to be re-written around task execution, not just Q&A. If you build on iOS, assume background automation, multi-step actions, and deeper app control become table stakes surfaces to integrate with, not optional extensions.
Applied AIApple’s New CEO Is Reportedly Pushing to Stuff More AI into iPhones
If John Ternus is leaning on software to accelerate beyond Siri, Apple is about to turn the iPhone into a much denser AI runtime, not just a client for cloud models. If you build consumer apps, assume tighter OS-level AI integration and start planning for Apple-native agent hooks and on-device inference competing with your own UX.
Applied AIDeepSeek’s AI Agent Platform Hits 1.54 Million Daily Users
1.54 million daily users on an AI agent infrastructure built around open source is a concrete proof point that agentic workflows can scale beyond demos. If you’re betting only on proprietary Western stacks, you now have to price in a parallel ecosystem where open models plus vertical agents become a credible default, especially in China and adjacent markets.